VFI and Seppic announce co-development of a GMP emulsion-based adjuvant for human prophylactic vaccines (including COVID-19 vaccines) on an open-access basis

VFI and Seppic announced that they have finalized the development of an oil-in-water adjuvant at a Seppic plant in France. The adjuvant, manufactured under Good Manufactured Practices, will be openly available from Seppic before the end of this year, for the entire vaccine community. Read press release.